19 November 2018 | News
People battling complex chronic pain conditions can now use the DRG Invisible Trial System to try Abbott's dorsal root ganglion (DRG) stimulation.
Abbott has announced the launch of the new DRG Invisible Trial System, which is approved by the U.S. Food and Drug Administration (FDA) and received CE Mark in Europe. People battling complex chronic pain conditions can now use the DRG Invisible Trial System to try Abbott's dorsal root ganglion (DRG) stimulation—a clinically proven, non-opioid treatment option for targeted chronic pain management.
Patients who find adequate pain relief with DRG therapy can then have Abbott's Proclaim DRG system implanted, empowering them to manage their pain with familiar Apple consumer technology.
A form of neurostimulation, Abbott's DRG therapy specifically targets the dorsal root ganglion—a structure adjacent to the spinal cord densely populated with sensory nerves that transmit chronic pain to the central nervous system.
The therapy helps people living with neuropathic pain conditions by blocking pain signals with electrical pulses transmitted over the DRG. Clinical research, such as the ACCURATE study, has demonstrated that DRG therapy can provide superior pain relief when compared to traditional spinal cord stimulation (SCS) therapy for patients with persistent neuropathic focal pain conditions. Focal chronic pain conditions, including complex regional pain syndrome (CRPS), are some of the most prevalent and under-treated forms of chronic pain around the world.